Florida Urologist opportunity. Stellar doctor needed to join three BC Urologists. The preferred candidate must have Laparoscopic and/or Robotic Training. Group is offering a salary,production bonus, a...
Johns Hopkins Researchers at Neuroscience 2008 - Table grapes are high in flavonoids, which are thought to have strong antioxidant and anti-inflammatory properties. Now, researchers at the Johns Hopkins University School of Medicine have shown that powdered grapes appear to reduce pain and inflammation in a rat model of arthritis, where rats knees are inflamed using a chemical injection.
UCB today announced the results of two phase III studies, published in the Annals of the Rheumatic Diseases Online, showing Cimzia® (certolizumab pegol), the only PEGylated anti-TNFalpha (Tumour Necrosis Factor alpha), provided significant clinical benefits as monotherapy, and in combination with methotrexate, in adults with active rheumatoid arthritis (RA).
LED Technologies, LLC announced today that the U.S. Food and Drug Administration (FDA) cleared their DPL™ Therapy System for the relaxation of muscles and relief of muscle spasms, temporary relief of minor muscle and joint aches, pains and stiffness; temporary relief of minor pain and stiffness associated with arthritis; and to temporarily increase local blood circulation.
Diabetes Mellitus is one of the most common chronic disorders in the population, affecting some 2 million people in the UK. Patients with diabetes (both Type 1 and 2) suffer an array of rheumatic complaints which are wide-ranging in nature and are often complex in management.
CEL-SCI Corporation (NYSE: CVM) announced the presentation of new rheumatoid arthritis data at the 6th annual GTCbio Vaccine Conference in Vienna, Va. The data, presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology of CEL-SCI, indicate that CEL-SCI's rheumatoid arthritis treatment vaccine CEL-2000 prevents or retards the permanent tissue damage caused by rheumatoid arthritis.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the publication of preclinical data from its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF.
